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Background Acute myocardial infarction is known as an acute metabolic stress, but clinicians currently have limited
guidance regarding the evaluation and management of hyperglycemia after revascularization.
Methods and results We assessed the prognostic role of three different ranges of in-hospital peak glycemia ( < 140, 140–
180, and >180mg/dl) in 252 acute ST-segment elevation myocardial infarction patients without earlier known diabetes
submitted to percutaneous coronary intervention consecutively admitted to our intensive cardiac care unit (ICCU). Patients
with highest peak glycemia showed the highest intra-ICCU mortality (7/44, 15.9%), which was significantly higher with
respect to the other two subgroups (P=0.001 and 0.034, respectively). At backward stepwise logistic regression analysis,
peak glycemia (odds ratio: 3.14; 95% confidence interval: 1.01–9.74, P=0.047) was an independent predictor of intra-ICCU
mortality.
Conclusion In acute ST-segment elevation myocardial infarction patients without earlier known diabetes submitted to
mechanical revascularization, the poorer in-hospital glucose control was associated with higher mortality; peak glycemia
greater than 180mg/dl was associated with the highest mortality, whereas patients with peak glycemia comprised
between 140 and 180mg/dl exhibited intermediate mortality rates. According to our data during hospitalization intensivists
should achieve glucose control values less than 140mg/dl, as peak glycemia resulted in the independent predictor of
intra-ICCU mortality. Eur J Cardiovasc Prev Rehabil 17:419–423 c 2010 The European Society of Cardiology
European Journal of Cardiovascular Prevention and Rehabilitation 2010, 17:419–423
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Introduction
Acute myocardial infarction (AMI) is known as an acute
metabolic stress whose components consists of a rapid rise
in blood glucose mainly due to an increase in plasma
catecholamines and plasma fatty-free acids [1]. Admission
high blood glucose levels in patients with acute coronary
syndrome (ACS) are common and are associated with an
increased risk of death [2–4].Most earlier studies have
focused mainly on the prognostic value of admission glucose.
Despite a growing body of knowledge about the
prognostic importance of elevated glucose in ACS
and some evidence of improved outcomes from tight
glucose control in other critically ill populations [5,6],
clinicians currently have limited guidance regarding
the evaluation and management of hyperglycemia in the
ACS setting, and in particular in the acute phase after
revascularization.
It has been recently stated [2] that in ACS patients
admitted to an intensive care unit (ICU), it is reasonable to
consider intensive glucose control in those with significant
hyperglycemia (i.e. plasma glucose >180mg/dl). In con-
trast, strategies for the management of patients with milder
degrees of hyperglycemia are far to be elucidated.
In particular, the precise goal of treatment has not yet
been defined and the suggested range for plasma glucose is
90–140mg/dl [2].
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The aim of this investigation was to assess the prognostic
role of three different ranges of in-hospital peak glycemia
(<140, 140–180, and >180mg/dl) in 252 ST-elevation
myocardial infarction (STEMI) patients without earlier
known diabetes submitted to percutaneous coronary
intervention (PCI) consecutively admitted, after me-
chanical revascularization, to our intensive cardiac care
unit (ICCU).
Methods
In a prospective study, from 1 January 2006 to 31 July
2007, 252 consecutive patients with STEMI (within 12 h
from symptoms’ onset) and without earlier known
diabetes were admitted to our ICCU, which is located
at the tertiary center. In our hospital, in Florence, the
reperfusion strategy of STEMI patients is represented by
primary PCI [7]. STEMI patients are first evaluated by
the Medical Emergency System staff in the prehospital
setting and then directly admitted to the catheterization
laboratory or transferred to it after a rapid stabilization
in the first aid. After primary PCI, they are admitted to
our ICCU. In the same period, 106 STEMI patients with
diabetes were consecutively admitted to our ICCU but,
because of diabetes, they were excluded from the study.
A successful procedure was defined as an infarct artery
stenosis less than 20% associated with thrombolysis in
myocardial infarction (TIMI) grade 3 flow. Failure PCI
was defined as resulting in TIMI grade 0–2 flow,
regardless the residual stenosis [8]. None of the patients
were on any chronic anti-inflammatory agent.
Study population
The diagnosis of STEMI was based on the criteria of
the American College of Cardiology/American Heart
Association [9].
On ICCU admission, soon after PCI, blood samples were
obtained for glucose, cardiac biomarkers [creatine phos-
phokinase (CPK): 20–160U/l, CPK-myocardial band
(MB): 0.5–3.6 ng/ml, Tn I<0.15 ng/ml], and creatinine
serum levels (0.6–1.5mg/dl), C-reactive protein (<9mg/dl),
erythrocyte sedimentation rate (ESR, 2–25mm/h),
leucocytes count (4000–10 000/ml), fibrinogen (200–
450mg/dl), lactic acid (0.6–1.7mmol/l), hemoglobin A1c
(HbA1c) values (<6.5%), and N-terminal pro-B-type
natriuretic peptide measurements (males: 0–50 years:
< 88 pg/ml; > 50 years: < 227 pg/ml, females: 0–50
years: < 153 pg/ml; > 50 years < 334 pg/ml) [10,11].
Transthoracic two-dimensional echocardiography was
performed on ICCU admission to measure the left
ventricular (LV) ejection fraction. Glycemia was assessed
three times a day throughout the ICCU stay. Patients
were stratified into three groups according to peak
glycemia: G1: less than 140mg/l, G2: 140–180mg/l),
and G3: >180mg/l.
Intensive insulin therapy was administered in patients
with significant hyperglycemia (i.e. plasma glucose
>180mg/dl). The study protocol was in accordance with
the Declaration of Helsinki and approved by the local
Ethics Committee. Informed consent was obtained from
all patients before enrollment.
Statistical analysis
Categorical data are expressed as frequencies and
percentages; continuous data are reported as median
(25–75th percentile). Univariate analysis (w2, Fisher’s
exact test for categorical data; Mann–Whitney U-test
and/or Kruskal–WallisH-test for continuous data) was used
to identify candidate variables for multivariate analysis
using a threshold P value of less than 0.05. Backward
stepwise logistic regression was performed to assess
whether hyperglycemia was the predictor of in-hospital
mortality. A P value of less than 0.05 was considered
significant. Analysis was carried out using SPSS 11.5
statistical package (SPSS Inc., Chicago, Illinois, USA).
Results
Table 1 shows the clinical characteristics of STEMI
patients included in the study, according to the peak
glucose values. In our series, 12 patients (4.7%) pre-
sented with cardiogenic shock and eight patients with
cardiac arrest (3.2%). Renal failure was present in 12
patients (4.2%). During the ICCU stay, most of the
patients (152/252; 59.9%) exhibited peak glucose values
less than 140mg/dl. Higher peak glucose levels were
associated with more advanced age (P=0.001), a higher
incidence of renal failure (P=0.009), a higher Killip class
(P=0.002), and a lower LV ejection fraction (P<0.001).
In the overall population, intra-ICCU mortality was 4.7%
(12/252). Patients in G3 showed the highest intra-ICCU
mortality (7/44, 15.9%), which was significantly higher
with respect to the patients in both G1 (P=0.001) and
G2 (P=0.034). No differences were observed among the
three subgroups (Table 2) with respect to the extension
of coronary artery disease, myocardial infarction location,
TIMI flow post procedure, and incidence of PCI failure.
Patients in G3 exhibited a higher incidence of TIMI flow
0–1 preprocedure.
Biochemical data are depicted in Table 3. Highest peak
glucose levels were associated with the highest fasting
glucose values (P<0.001), CPK, CPK-MB, and Tn I
(P=0.005, 0.001, and 0.003, respectively). None of the
patients in G1 showed HbA1c values greater than 6.5%,
whereas patients in G2 and G3 showed a higher incidence
of HbA1c, that is, values greater than 6.5% (G2: 41.7%;
G3: 81.1%, respectively). N-terminal pro-B-type natriure-
tic peptide levels were higher in G3 patients (P=0.003),
and lactic acid (P<0.001).
At backward stepwise logistic regression analysis, the
following variables resulted as independent predictors of
in ICCU mortality: age [odds ratio (OR): 1.12; 95%
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Table 1 Clinical characteristics of patients included in the study
Peak glycemia (g/dl)
Variable frequency (%) or median
(25–75th percentile) G1: < 1.40 (n=151) G2: 1.40–1.80 (n=57) G3: >1.80 (n=44)
P
w2 or Kruskal–Wallis H test
Females/males 32/119 (21.2/78.8) 16/41 (28.1/71.9) 13/31 (29.5/70.5) 0.388
Age (years) 62 (55–73) 69 (62–76) 71 (59–78) 0.001
Weight (kg) 74 (65–82) 74 (66–84) 75 (65–82) 0.944
BMI (kg/m2) 25.7 (23.5–28.0) 25.5 (23.8–29.7) 26.7 (23.7–28.6) 0.424
Hypertension 65 (43.0) 30 (52.6) 24 (54.5) 0.263
Dyslipidemia 58 (38.4) 30 (52.6) 18 (40.9) 0.177
Smoke
No smoke 56 (37.3) 26 (45.6) 27 (61.4) 0.067
Earlier smoke 76 (50.7) 27 (47.4) 14 (31.8)
Ever smoke 18 (12.0) 4 (7.0) 3 (6.8)
Comorbidities 27 (17.9) 12 (21.1) 14 (31.8) 0.136
Renal failure 4 (2.6) 2 (3.5) 6 (13.6) 0.009
COPD 8 (5.3) 4 (7.0) 3 (6.8) 0.865
Earlier MI 16 (10.6) 5 (8.8) 9 (20.5) 0.146
Earlier angina 23 (15.2) 10 (17.6) 5 (11.4) 0.688
Earlier PCI 20 (13.2) 7 (12.3) 6 (13.6) 0.977
Earlier CABG 1 (0.7) 0 0 0.715
Killip class
I 132 (88.0) 43 (75.4) 33 (75.0) 0.002
II 14 (9.3) 5 (8.8) 2 (4.5)
III 1 (0.7) 3 (5.3) 1 (2.3)
IV 3 (2.0) 6 (10.5) 8 (18.2)**
AMI location
Inferior 67 (44.4) 22 (38.6) 14 (31.8) 0.472
Lateral 9 (6.0) 6 (10.5) 3 (6.8)
Anterior 75 (49.7) 29 (50.9) 27 (61.4)
LVEF (%) 48 (40–52) 40 (35—48) 40 (26–47) <0.001
Dead patients
ICCU (2004–2007) 3 (2.0) 2 (3.5) 7 (15.9)** 0.001
Follow-up (n=152; 2004–2006) 5 (5.4) 0 1 (3.4) 0.401
Total (n=162; 2004–2006) 8 (8.4) 1 (3.1) 7 (20.0) 0.052
AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary-artery bypass graft; COPD, chronic obstructive pulmonary disease; ICCU, intensive cardiac
care unit; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention. **P<0.01.
Table 2 Angiographic data of patients included in the study
Peak glycemia (g/dl)
Variable frequency (%) or median
(25–75th percentile) G1: < 1.40 (n=151) G2: 1.40–1.80 (n=57) G3: >1.80 (n=44)
P
w2 or Kruskal–Wallis H test
Coronary artery disease
No disease 2 (1.3) 0 (0.0) 0 (0.0) 0.571
1 vessel 55 (36.4) 24 (42.1) 14 (31.8)
2 vessel 57 (37.7) 17 (29.8) 18 (40.9)
3 vessel 36 (23.8) 14 (24.6) 12 (27.3)
CABG 1 (0.7) 2 (3.5) 0 (0.0)
Left main 8 (5.3) 5 (8.8) 2 (4.5) 0.583
Collateral branches 13 (8.6) 8 (14.0) 6 (13.6) 0.417
TIMI flow pre—PCI
III 9 (6.0) 0 (0.0) 1 (2.3) 0.033
II 10 (6.6) 4 (7.0) 0 (0.0)
I 19 (12.6) 6 (10.5) 12 (27.9)*
0 113 (74.8) 47 (82.5) 31 (69.8)
IRA
RCA 58 (38.4) 21 (36.8) 10 (22.7) 0.443
CX 15 (9.9) 6 (10.5) 7 (15.9)
LDA 76 (50.3) 28 (49.1) 26 (59.1)
Left main 0 (0.0) 1 (1.8) 1 (2.3)
CABG 2 (1.3) 1 (1.8) 0 (0.0)
Stent implantation 137 (90.7) 53 (93.0) 37 (84.1) 0.305
TIMI flow postPCI
III 140 (92.7) 51 (89.5) 39 (88.4) 0.598
II 8 (5.3) 4 (7.0) 4 (9.3)
I 1 (0.7) 2 (3.5) 1 (2.3)
0 2 (1.3) 0 (0.0) 0 (0.0)
PCI failure abciximab 10 (6.6) 6 (10.5) 5 (11.4) 0.480
CABG, coronary artery bypass; CX, left circumflex artery; IRA, infarct-related artery; LDA, left descending artery; PCI, percutaneous coronary intervention; RCA, right
coronary artery; TIMI, thrombolysis in myocardial infarction. *P<0.05.
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confidence interval (CI): 1.02–1.24, P=0.021]; LV ejection
fraction (OR: 0.88; 95% CI: 0.80–0.96, P=0.004); Tn I
(OR: 1.004; 95% CI: 1.000–1.008, P=0.042); and peak
glycemia (OR: 3.14; 95% CI: 1.01–9.74, P=0.047).
Discussion
In patients with STEMI, hyperglycemia is common and
frequently untreated [2]. Most earlier studies have
focused predominantly on the prognostic value of admis-
sion glucose [2], whereas three earlier investigations
suggest that hyperglycemia after hospital admission holds
a more important prognostic significance than admission
hyperglycemia. Suleiman et al. [12] observed that the
addition of fasting glucose levels within 24 h of hospitali-
zation to the admission glucose values improved the
ability of the model to predict 30-day mortality rates.
Svensson et al. [13] showed that hyperglycemia on arrival
and hypoglycemia during hospitalization are both inde-
pendently associated with worse adjusted all-cause 2-year
mortality risk. Finally, Goyal et al. [14] assessed the effect
of the change between 24 h and admission glucose levels
and death, and documented that an increase in glucose
values during the first 24 h of hospitalization was
associated with higher 30-day and 180-day mortality rates.
Kosiborod et al. [15] documented that in elderly AMI
patients, particularly those without recognized diabetes
elevated glucose is common, rarely treated, and asso-
ciated with increased mortality risk.
Moreover, in STEMI patients the benefits of treating
hyperglycemia have not been established definitively
and the target value of blood glucose to be achieved with
treatment remains undefined [2]. Earlier randomized
clinical trials of glucose control in ACS have been limited
primarily to patients with known diabetes, and their
results have been inconsistent due to the different patient
selections, and the wide variation in glucose targets [16–21].
In contrast, studies in critically ill patients show that
successful strict glucose control may result in better
outcomes. In particular, a landmark study by van den
Berghe et al. [5] showed that target-driven glucose control
with intensive insulin therapy (goal of whole blood glucose
level of 80–110mg/dl) reduced ICU mortality rates from
8.0 to 4.6% in surgical patients and in-hospital mortality
rates from 10.9 to 7.2%. This improvement was more
pronounced in patients with an ICU stay of more than 5
days. Obviously, as the significant differences in patient
populations, the results of the studies carried out in critical
illness by van den Berghe et al. [5] cannot simply be
extrapolated to patients with ACS, mainly because many
patients with ACS have ICU stays shorter than 3 days.
In contrast, in the recent guidelines [2], as the paucity
of data on glucose control in ACS, intensive glucose
control in patients with significant hyperglycemia (plasma
glucose>180mg/dl) is considered reasonable (level of
evidence B) regardless of earlier diabetes history, whereas
in patients with milder degrees of hyperglycemia efforts
to optimize glucose levels are suggested. Kosiborod et al.
[22] documented that measures of persistent hypergly-
cemia during AMI are better predictors of mortality than
admission glucose.
The main finding of this investigation, performed in
nondiabetic STEMI patients submitted to mechanical
revascularization, was that the poorer in-hospital glucose
control was associated with higher mortality; in particular,
peak glycemia greater than 180mg/dl was associated with
the highest mortality, whereas patients with peak glycemia
comprised between 140 and 180mg/dl exhibited inter-
mediate mortality rates.
Acute glycemic variations are associated with a pro-
thrombotic status related to several alterations of the
hemostatic pathway, including lengthening of fibrinogen
half-life, increased number of prothrombin fragments,
factor VII, and in platelet aggregation [23]. Hyperglyce-
mia per se induces a proinflammatory state, which
includes both cellular and oxidative stress. At the cellular
level, glucose is known to increase proinflammatory
transcriptor factors (such as intranuclear nuclear factor-
kappa B binding, activator protein-1, and early growth
response-1) that are suppressed by insulin. In the
presence of high glucose concentrations, several steps
Table 3 Biochemical data of patients included in the study
Peak glycemia (g/dl)
Variable frequency (%) or median
(25–75th percentile) G1: < 1.40 (n=151) G2: 1.40–1.80 (n=57) G3: > 1.80 (n=44)
P
w2 or Kruskal–Wallis H test
Glycemia (g/l) 1.15 (1.03–1.23) 1.53 (1.47–1.64) 1.92 (2.28–2.34) < 0.001
HbA1c (%) 0 41.7 81.1 <0.001
NT-proBNP 1441 (418–2781) 1860 (584–3031) 3032 (948–4698) 0.003
Lactic acid 1.50 (1.00–1.90) 1.90 (1.60–2.30) 2.30 (1.73–3.50) < 0.001
CPK (U/l) 1572 (799–3015) 2371 (1356–4584) 2578 (1290–4518) 0.005
CK-MB (ng/ml) 172.0 (93.1–308.0) 297.0 (152.2–544.8) 291.0 (135.2–496.5) 0.001
Peak Tn I (ng/ml) 62.7 (33.0–129.0) 100.3 (55.9–224.5) 116.4 (51.9–199.8) 0.003
Creatinine (mg/dl) 1.00 (0.80–1.10) 1.00 (0.80–1.10) 1.10 (0.92–1.28) 0.003
Insulin resistance (HOMA>2) 62 (41.1) 36 (63.2) 36 (81.8) < 0.001
CK, creatine kinase; CPK, creatine phosphokinase; ESR, erythrocyte sedimentation rate; HbA1c; hemoglobin A1c; HOMA, homeostatic model assessment; MB,
myocardial band; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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of the glycolytic pathways can induce the release of
toxic derivatives, including polyols derived from glucose,
hexosamines from fructose-6-phosphate, advanced glyca-
tion products, and activators of the protein kinase C
pathway from glyceraldehyde-3-phosphate. Vulnerability
to glucose toxicity may also be due to increased gene-
ration of or deficient scavenging systems for radical
oxygen species produced by activated glycolysis and
oxidative phosphorylation. During hypoxia-reperfusion
superoxide production is increased and when, in this
setting, cells are also overloaded with glucose, high levels
of superoxide (together with nitric oxide metabolites)
contribute to mitochondrial dysfunction. This phenom-
enon supports the hypothesis that in STEMI patients
even in the postrevascularization phase, glucose control
should be optimized [23–26].
Our results are in agreement with the recent paper by
Kosiborod et al. [25] who reported that based on the data
of approximately 7800 patients with AMI glucose normali-
zation after admission is associated with better survival in
hyperglycemic patients.
Limitation of the study
The main limitation is represented by the small number
size in this single-center study. However, the patient
population is unselected and homogeneous comprising
consecutive STEMI without earlier known diabetes
patients all submitted to mechanical revascularization.
Conclusion
In STEMI patients without earlier known diabetes, peak
glycemia was found to be an independent predictor for
intra-ICCU mortality. In particular peak glycemia greater
than 180mg/dl was associated with the highest mortality,
whereas patients with peak glycemia comprised between
140 and 180mg/dl exhibited intermediate mortality rates.
Thus, intensivists should consider intra-ICCU glucose
control as a therapeutic goal, with a target less than
140mg/dl.
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